Achilles Therapeutics plc (ACHL) Bundle
An Overview of Achilles Therapeutics plc (ACHL)
General Summary of Achilles Therapeutics plc (ACHL)
Achilles Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing personalized cell therapies targeting solid tumors. Founded in 2016 and headquartered in London, UK, the company specializes in precision T-cell therapies.
Key Company Characteristics
- Incorporated: 2016
- Headquarters: London, United Kingdom
- Stock Exchange: NASDAQ
- Ticker Symbol: ACHL
Financial Performance (Latest Reporting Period)
| Financial Metric | Amount (USD) |
|---|---|
| Cash and Cash Equivalents | $78.4 million |
| Research and Development Expenses | $45.2 million |
| Net Loss | $52.6 million |
Product Pipeline
- ACHL-001: Precision T-cell therapy for lung cancer
- ACHL-002: Personalized cell therapy for solid tumors
Clinical Development Status
Currently conducting Phase 1/2 clinical trials for precision T-cell therapies targeting specific patient populations with solid tumors.
Industry Leadership
Achilles Therapeutics is recognized for its innovative approach to personalized cancer immunotherapy, utilizing proprietary PELEUS™ platform to identify and target tumor-specific mutations.
| Research Focus | Details |
|---|---|
| Technology Platform | PELEUS™ Precision T-cell Platform |
| Primary Research Area | Personalized Cancer Immunotherapy |
Investor and Market Information
- Initial Public Offering (IPO): January 2021
- IPO Price: $17 per American Depositary Share
- Total Funding Raised: Approximately $190 million
Mission Statement of Achilles Therapeutics plc (ACHL)
Mission Statement of Achilles Therapeutics plc (ACHL)
Achilles Therapeutics plc focuses on developing personalized T cell therapies targeting cancer through precision immunotherapy.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Precision Immunotherapy | Clonal Neoantigens Targeting | 3 Advanced Clinical Trials in 2024 |
| Personalized T Cell Therapy | Patient-Specific Cancer Treatment | 2 Clinical Programs Active |
| Cancer Research | Advanced Genomic Approaches | £34.2M Research Investment |
Research Strategy
- Proprietary PELEUS Platform Technology
- Machine Learning Genomic Analysis
- Personalized Neoantigen Identification
Clinical Development Focus
Achilles Therapeutics concentrates on solid tumor immunotherapies with specific emphasis on:
- Non-Small Cell Lung Cancer
- Metastatic Melanoma
- Advanced Stage Solid Tumors
Financial Investment Metrics
| Category | 2024 Allocation |
|---|---|
| R&D Expenditure | £42.6M |
| Clinical Trial Funding | £18.3M |
| Technology Development | £12.7M |
Key Performance Indicators
2024 Clinical Development Metrics:
- 3 Ongoing Clinical Trials
- 2 Phase II Clinical Programs
- Patient Cohort: 87 Enrolled Patients
Vision Statement of Achilles Therapeutics plc (ACHL)
Vision Statement Overview of Achilles Therapeutics plc (ACHL)
Precision Immunotherapy FocusAchilles Therapeutics plc aims to develop personalized T-cell therapies targeting specific cancer mutations. As of 2024, the company concentrates on advanced solid tumor treatments.
Strategic Vision Components
Tumor-Specific Targeting StrategyThe company's vision centers on developing precision immunotherapies that leverage unique tumor-specific mutations for patient treatment.
| Vision Aspect | Specific Focus | Target Indication |
|---|---|---|
| Personalized Therapy | Patient-specific T-cell approaches | Solid tumor treatments |
| Mutation Targeting | Clonal neoantigens | Advanced cancer types |
Technology Platform Objectives
Proprietary Technology Development- ACHL-103 clinical development program
- Precision immunotherapy platform
- Patient-specific T-cell engineering
Research and Development Vision
Achilles Therapeutics focuses on advancing its ACHL-103 program targeting lung cancer and other solid tumors.
| Research Parameter | 2024 Status |
|---|---|
| Clinical Trials | Phase 1/2 ongoing |
| Research Investment | $28.4 million allocated |
Global Healthcare Impact
Achilles Therapeutics seeks to transform cancer treatment through innovative immunotherapy approaches targeting patient-specific tumor mutations.
Core Values of Achilles Therapeutics plc (ACHL)
Core Values of Achilles Therapeutics plc (ACHL)
Patient-Centric Innovation
Achilles Therapeutics focuses on developing personalized cancer immunotherapies targeting clonal neoantigens.
| Research Focus | Key Metrics |
|---|---|
| Personalized Cancer Immunotherapy | ACHL-103 and ACHL-107 clinical trials in progress |
| Neoantigen Targeting Platform | Proprietary PELEUS™ technology platform |
Scientific Excellence
Commitment to advanced scientific research and technological development.
- Collaboration with University College London
- Advanced genomic profiling technologies
- Multi-disciplinary research approach
Transparency and Ethical Research
Maintaining highest standards of clinical research and data integrity.
| Regulatory Compliance | Details |
|---|---|
| Clinical Trial Registrations | NCT04262999, NCT04491916 |
| Ethical Review Board Approvals | Multiple international approvals |
Collaborative Innovation
Strategic partnerships to advance cancer immunotherapy research.
- Partnership with The Royal Marsden NHS Foundation Trust
- Collaboration with leading academic institutions
- Joint research initiatives
Financial Commitment to Research
Significant investment in research and development.
| Financial Metric | 2023 Value |
|---|---|
| R&D Expenditure | £24.3 million |
| Cash and Cash Equivalents | £57.6 million (as of December 31, 2023) |
Achilles Therapeutics plc (ACHL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.